Research Article: Competing treatments for migraine: a headache for decision-makers
Abstract:
Migraine is the world’s second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year. Several costly new drugs have been approved by National Institute for Health and Care Excellence.
Introduction:
Migraine is one of the most common and debilitating neurological disorders globally and is the second leading cause of years lived with disability worldwide [1]. Average global migraine prevalence is reported as 12% (range: 2.6% and 21.7%), with variation between countries and between studies conducted in the same country [2]. Migraine is more common among women [3, 4] and also more prevalent among the 35–42 years age group [5]. The frequency of migraine episodes determines its classification: up to 14 migraine…
Read more